Company Encyclopedia
View More
name
Traws Pharma
TRAW.US
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University.
4.514 T
TRAW.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking98/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-728.98%E
    • Profit Margin-467.64%E
    • Gross Margin0.00%E
  • Growth ScoreA
    • Revenue YoY1159.29%A
    • Net Profit YoY75.54%A
    • Total Assets YoY39.25%A
    • Net Assets YoY323.56%A
  • Cash ScoreB
    • Cash Flow Margin-31.08%D
    • OCF YoY1159.29%A
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreD
    • Gearing Ratio63.47%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. Stock Market Midday Update: Target Price Increase Boosts Traws Pharma by 13.27%, Confidence in the Pharmaceutical Industry Soars

    Traws Pharma rose 13.27%; Eli Lilly fell 1.88%, with a trading volume of USD 2.417 billion; Johnson & Johnson fell 1.52%, with a trading volume of USD 877 million; Novo Nordisk rose 1.10%, with a trading volume of USD 773 million; AstraZeneca fell 0.68%, with a market capitalization of USD 279.9 billion

    Tracking Unusual Activity·
    US
    TRAW
    +11.85%
    Tracking Unusual Activity·
    US
    TRAW
    +11.85%

    Traws Pharma Inc. Held Annual Shareholder Meeting

    Traws Pharma Inc. held its annual shareholder meeting on November 21, 2025, where all nominated directors were elected to the board. Stockholders approved amendments to the company's incentive compensation plan, increasing shares reserved for issuance and extending the plan's term.

    Reuters·
    US
    TRAW
    +11.85%
    Reuters·
    US
    TRAW
    +11.85%

    Traws Pharma | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TRAW
    +11.85%
    LB filings·
    US
    TRAW
    +11.85%

    Traws Pharma Reports Q3 2025 Financial Results

    Traws Pharma announced Q3 2025 financial results, highlighting cost reductions, intellectual property acquisitions, and a strategic shift towards antiviral programs. The company is advancing Phase 2 studies for COVID-19 and flu therapies. Despite a decrease in net loss, Spark rates TRAW stock as Underperform due to financial challenges. Recent positive trial data and new financing offer hope for future improvements. Traws Pharma focuses on developing therapies for respiratory viral diseases, targeting significant market opportunities.

    Tip Ranks·
    US
    TRAW
    +11.85%
    Tip Ranks·
    US
    TRAW
    +11.85%

    Traws Pharma | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TRAW
    +11.85%
    LB filings·
    US
    TRAW
    +11.85%
    © 2025 Longbridge｜Disclaimer